CN105031540A - Traditional Chinese medicine for treating ischemic femoral head necrosis - Google Patents
Traditional Chinese medicine for treating ischemic femoral head necrosis Download PDFInfo
- Publication number
- CN105031540A CN105031540A CN201510518675.XA CN201510518675A CN105031540A CN 105031540 A CN105031540 A CN 105031540A CN 201510518675 A CN201510518675 A CN 201510518675A CN 105031540 A CN105031540 A CN 105031540A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- grams
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a traditional Chinese medicine for treating ischemic femoral head necrosis, which comprises the following substances in parts by weight: red ginseng, astragalus root, ass-hide glue, earthworm, angelica, chuanxiong rhizome, fried bighead atractylodes rhizome, fried haricot bean, white peony root, radix curcumae, antler, deer bone, cibotium barometz, sealwort, pseudo-ginseng, saffron, ground beetle, dioscorea nipponica, dragon blood, achyranthes root, dipsacus root, elderberry, clematis root, fructus psoraleae, rhizoma gastrodiae, notopterygium root, red sage root, giant knotweed, broadleaf globethistle inflorescence and homalomena rhizoma. The traditional Chinese medicine provided by the invention has the effects of regulating the flow of qi and nourishing the blood, harmonizing the stomach and strengthening the spleen, tonifying the kidneys and nourishing the liver, strengthening the tendons and bones, repairing and nourishing the bones and reconstructing the dead bones. The traditional Chinese medicine is mainly used for treating ischemic femoral head necrosis at each stage, bone injury, bone fracture, deterioration of muscles and bones, bone calcification, osteoporosis, rheumatism, rheumatoid arthritis, lumbocrural pain, arthralgia, sciatica and the like.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of Chinese drugs agentia for the treatment of bone stock head ischemic necrosis.
Background technology
Ischemic necrosis of femoral head is also called femur head necrosis, is one of common disease of orthopaedics, and young and middle-aged and elderly population all can be fallen ill, but increases with the age due to elderly population, and body constitution is poor, and self-protection ability is not good enough, thus sickness rate more young and middle-aged be height.The blood supply of the femoral head occurring mainly to cause due to different reason interrupts or destroys, osteocyte and marrow components death, osteocyte degeneration, bone have vigor composition dead gradually, then cause capital mechanical strength to reduce, structure changes, collapse of the femoral head is out of shape, and obstacle appears in function of joint.Chinese medicine is thought, belong to the categories such as " arthromyodynia ", " rheumatism involving the bone ", " myopathy ", " atrophic debility of bones ", its reason is due to congenital kidney qi virtual loss, is subject to wound the day after tomorrow, or being invaded by exogenous pathogen, or lose in moisten foster caused by.Because the course of disease is longer, treat not easily, and disability rate is very high, brings serious commercial burden and mental pressure to patient, drastically influence the study of people, work and life, therefore, positive treatment be given.
Summary of the invention
The object of this invention is to provide a kind of Chinese drugs agentia for the treatment of bone stock head ischemic necrosis.
In order to realize object of the present invention, the invention provides a kind of Chinese drugs agentia for the treatment of bone stock head ischemic necrosis, it comprises the material of following weight portion: Radix Ginseng Rubra 15-25 part, Radix Astragali 20-50 part, Colla Corii Asini 10-20 part, Pheretima 10-15 part, Radix Angelicae Sinensis 10-25 part, Rhizoma Chuanxiong 10-25 part, Rhizoma Atractylodis Macrocephalae (parched) 10-15 part, stir-fried kidney beans 10-25 part, Radix Paeoniae Alba 10-20 part, Radix Curcumae 10-25 part, Cornu Cervi Pantotrichum 10-15 part, Os Cervi 20-30 part, Rhizoma Cibotii 10-30 part, Rhizoma Polygonati 20-30 part, Radix Notoginseng 50-100 part, Stigma Croci 10-15 part, Eupolyphaga Seu Steleophaga 10-25 part, Rhizoma Dioscoreae Nipponicae 10-25 part, Sanguis Draxonis 10-30 part, Radix Achyranthis Bidentatae 10-30 part, Radix Dipsaci 15-25 part, Ramulus Sambuci Williamsii 20-50 part, Radix Clematidis 15-25 part, Fructus Psoraleae 20-30 part, Rhizoma Gastrodiae 15-25 part, Rhizoma Et Radix Notopterygii 20-25 part, Radix Salviae Miltiorrhizae 20-25 part, Rhizoma Polygoni Cuspidati 15-25 part, Flos Echinopsis latifolii 15-20 part and Rhizoma Homalomenae 15-20 part.
Preferably, the Chinese drugs agentia for the treatment of bone stock head ischemic necrosis of the present invention comprises the material of following weight portion: Radix Ginseng Rubra 20 parts, the Radix Astragali 30 parts, 15 parts, Colla Corii Asini, Pheretima 12 parts, Radix Angelicae Sinensis 20 parts, Rhizoma Chuanxiong 20 parts, Rhizoma Atractylodis Macrocephalae (parched) 12 parts, stir-fried kidney beans 20 parts, the Radix Paeoniae Alba 15 parts, Radix Curcumae 20 parts, 12 parts, Cornu Cervi Pantotrichum, Os Cervi 25 parts, Rhizoma Cibotii 20 parts, Rhizoma Polygonati 25 parts, Radix Notoginseng 80 parts, Stigma Croci 12 parts, Eupolyphaga Seu Steleophaga 20 parts, Rhizoma Dioscoreae Nipponicae 20 parts, Sanguis Draxonis 20 parts, Radix Achyranthis Bidentatae 20 parts, Radix Dipsaci 20 parts, Ramulus Sambuci Williamsii 30 parts, Radix Clematidis 20 parts, Fructus Psoraleae 25 parts, 20 parts, Rhizoma Gastrodiae, Rhizoma Et Radix Notopterygii 22 parts, Radix Salviae Miltiorrhizae 22 parts, Rhizoma Polygoni Cuspidati 20 parts, Flos Echinopsis latifolii 18 parts and Rhizoma Homalomenae 18 parts.
More preferably, the Chinese drugs agentia for the treatment of bone stock head ischemic necrosis of the present invention also comprises the material of following weight portion: blue 10 parts of Iris speculatrix Hance 20 parts, Herba Stellariae Alsines 16 parts, Conyza canadensis (L.) Cronq. 15 parts, Lignum Xanthoceratis 12 parts, Rauvolfia verticillata 15 parts, Herba hyperici attenuati 18 parts, fingernail, Ramulus Et folium Spiraeae Acuminatae 9 parts, Radix seu Folium Cinnamomi angustifolii 11 parts and Radix grewiae bilobae 10 parts.
Most preferably, described Chinese drugs agentia can be tablet, dispersible tablet, capsule, unguentum or decoction.
The present invention also provides the purposes of compositions in the Chinese medicine of preparation treatment bone stock head ischemic necrosis, described compositions comprises the material of following weight portion: Radix Ginseng Rubra 15-25 part, Radix Astragali 20-50 part, Colla Corii Asini 10-20 part, Pheretima 10-15 part, Radix Angelicae Sinensis 10-25 part, Rhizoma Chuanxiong 10-25 part, Rhizoma Atractylodis Macrocephalae (parched) 10-15 part, stir-fried kidney beans 10-25 part, Radix Paeoniae Alba 10-20 part, Radix Curcumae 10-25 part, Cornu Cervi Pantotrichum 10-15 part, Os Cervi 20-30 part, Rhizoma Cibotii 10-30 part, Rhizoma Polygonati 20-30 part, Radix Notoginseng 50-100 part, Stigma Croci 10-15 part, Eupolyphaga Seu Steleophaga 10-25 part, Rhizoma Dioscoreae Nipponicae 10-25 part, Sanguis Draxonis 10-30 part, Radix Achyranthis Bidentatae 10-30 part, Radix Dipsaci 15-25 part, Ramulus Sambuci Williamsii 20-50 part, Radix Clematidis 15-25 part, Fructus Psoraleae 20-30 part, Rhizoma Gastrodiae 15-25 part, Rhizoma Et Radix Notopterygii 20-25 part, Radix Salviae Miltiorrhizae 20-25 part, Rhizoma Polygoni Cuspidati 15-25 part, Flos Echinopsis latifolii 15-20 part and Rhizoma Homalomenae 15-20 part.
Preferably, described compositions comprises the material of following weight portion: Radix Ginseng Rubra 20 parts, the Radix Astragali 30 parts, 15 parts, Colla Corii Asini, Pheretima 12 parts, Radix Angelicae Sinensis 20 parts, Rhizoma Chuanxiong 20 parts, Rhizoma Atractylodis Macrocephalae (parched) 12 parts, stir-fried kidney beans 20 parts, the Radix Paeoniae Alba 15 parts, Radix Curcumae 20 parts, 12 parts, Cornu Cervi Pantotrichum, Os Cervi 25 parts, Rhizoma Cibotii 20 parts, Rhizoma Polygonati 25 parts, Radix Notoginseng 80 parts, Stigma Croci 12 parts, Eupolyphaga Seu Steleophaga 20 parts, Rhizoma Dioscoreae Nipponicae 20 parts, Sanguis Draxonis 20 parts, Radix Achyranthis Bidentatae 20 parts, Radix Dipsaci 20 parts, Ramulus Sambuci Williamsii 30 parts, Radix Clematidis 20 parts, Fructus Psoraleae 25 parts, 20 parts, Rhizoma Gastrodiae, Rhizoma Et Radix Notopterygii 22 parts, Radix Salviae Miltiorrhizae 22 parts, Rhizoma Polygoni Cuspidati 20 parts, Flos Echinopsis latifolii 18 parts and Rhizoma Homalomenae 18 parts.
More preferably, described compositions also comprises the material of following weight portion: blue 10 parts of Iris speculatrix Hance 20 parts, Herba Stellariae Alsines 16 parts, Conyza canadensis (L.) Cronq. 15 parts, Lignum Xanthoceratis 12 parts, Rauvolfia verticillata 15 parts, Herba hyperici attenuati 18 parts, fingernail, Ramulus Et folium Spiraeae Acuminatae 9 parts, Radix seu Folium Cinnamomi angustifolii 11 parts and Radix grewiae bilobae 10 parts.
Most preferably, described Chinese medicine can be tablet, dispersible tablet, capsule, unguentum or decoction.
Chinese drugs agentia of the present invention is regulated the flow of vital energy and is nourished blood, stomach function regulating spleen invigorating, the kidney invigorating nourishing the liver, and bone and muscle strengthening repaiies bone Psoralen, and sequestrum is heavily strong.Cure mainly purposes: each phase ischemic necrosis of femoral head, bone fracture, muscles and bones regression, sclerotin calcification, osteoporosis, rheumatic and rheumatoid, lumbago and skelalgia, arthralgia, sciatica etc.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment 1 capsule of the present invention
Take Radix Ginseng Rubra 200 grams, the Radix Astragali 300 grams, 150 grams, Colla Corii Asini, Pheretima 120 grams, Radix Angelicae Sinensis 200 grams, Rhizoma Chuanxiong 200 grams, Rhizoma Atractylodis Macrocephalae (parched) 120 grams, stir-fried kidney beans 200 grams, the Radix Paeoniae Alba 150 grams, Radix Curcumae 200 grams, 120 grams, Cornu Cervi Pantotrichum, Os Cervi 250 grams, Rhizoma Cibotii 200 grams, Rhizoma Polygonati 250 grams, Radix Notoginseng 800 grams, Stigma Croci 120 grams, Eupolyphaga Seu Steleophaga 200 grams, Rhizoma Dioscoreae Nipponicae 200 grams, Sanguis Draxonis 200 grams, Radix Achyranthis Bidentatae 200 grams, Radix Dipsaci 200 grams, Ramulus Sambuci Williamsii 300 grams, Radix Clematidis 200 grams, Fructus Psoraleae 250 grams, 200 grams, Rhizoma Gastrodiae, Rhizoma Et Radix Notopterygii 220 grams, Radix Salviae Miltiorrhizae 220 grams, Rhizoma Polygoni Cuspidati 200 grams, Flos Echinopsis latifolii 180 grams and Rhizoma Homalomenae 180 grams, pulverize, cross 100 mesh sieves, evenly be dispensed in 100 capsules, obtain.
Embodiment 2 capsule of the present invention
Take Radix Ginseng Rubra 200 grams, the Radix Astragali 300 grams, 150 grams, Colla Corii Asini, Pheretima 120 grams, Radix Angelicae Sinensis 200 grams, Rhizoma Chuanxiong 200 grams, Rhizoma Atractylodis Macrocephalae (parched) 120 grams, stir-fried kidney beans 200 grams, the Radix Paeoniae Alba 150 grams, Radix Curcumae 200 grams, 120 grams, Cornu Cervi Pantotrichum, Os Cervi 250 grams, Rhizoma Cibotii 200 grams, Rhizoma Polygonati 250 grams, Radix Notoginseng 800 grams, Stigma Croci 120 grams, Eupolyphaga Seu Steleophaga 200 grams, Rhizoma Dioscoreae Nipponicae 200 grams, Sanguis Draxonis 200 grams, Radix Achyranthis Bidentatae 200 grams, Radix Dipsaci 200 grams, Ramulus Sambuci Williamsii 300 grams, Radix Clematidis 200 grams, Fructus Psoraleae 250 grams, 200 grams, Rhizoma Gastrodiae, Rhizoma Et Radix Notopterygii 220 grams, Radix Salviae Miltiorrhizae 220 grams, Rhizoma Polygoni Cuspidati 200 grams, Flos Echinopsis latifolii 180 grams, Rhizoma Homalomenae 180 grams, Iris speculatrix Hance 200 grams, Herba Stellariae Alsines 160 grams, Conyza canadensis (L.) Cronq. 150 grams, Lignum Xanthoceratis 120 grams, Rauvolfia verticillata 150 grams, Herba hyperici attenuati 180 grams, blue 100 grams of fingernail, Ramulus Et folium Spiraeae Acuminatae 90 grams, Radix seu Folium Cinnamomi angustifolii 110 grams and Radix grewiae bilobae 100 grams, pulverize, cross 100 mesh sieves, evenly be dispensed in 100 capsules, obtain.
Experimental example
Diagnostic criteria
Formulate with reference to the relevant criterion in the reparation of the ischemic necrosis of femoral head " with reproduce " the 2nd edition.
(1) main standard
(1) medical history, symptom, sign: once there was trauma history in bones of the body portion, or used corticosteroid medication history, or have excessive drinking history, diving history, high-altitude flight history, blood medical history; Hip pain, position is mainly around thigh, groin and buttocks, and character is dull pain, aches or dull pain, the limitation of activity of bones of the body joint inward turning, and increasing the weight of appears in pain when inward turning; Or have cross mountains row, joint function disturbance and muscle weakness etc.
(2) x-ray performance: femoral head is collapsed mode, and joint space has no and narrows, hardenability band visible transmission band (the meniscus sign positive and subchondral bone folding) under cartilage of inner visible boundary.
(3) CT, MRI or radioisotope scanning etc. inspections support the diagnosis of femoral head pathological changes.
(2) minor criteria
(1) X-ray film: femoral head is in subsiding and narrow with joint space simultaneously, and occur that cystic becomes or the sclerosis of spottiness shape, capital outer top becomes flat.
(2) MRI: matter or the heterogeneous low signal intensity such as visible, the band shape with T1 phase changes.
Meet 2 in main standard or 3, can clarify a diagnosis; Meet 1 main standard or 2 minor criterias (wherein at least comprising the positive pathological changes of x-ray) are also clarified a diagnosis.
Staging scale
With reference to (Ficat) staging scale formulation by stages of luxuriant and rich with fragrance card.
Include case standard in
(1) age is between 20-60 one full year of life.
(2) above-mentioned diagnostic criteria person is met.
(3) the II phase person in above-mentioned luxuriant and rich with fragrance card staging scale is met.
Any related drugs or Regimen Chemotherapy person is not accepted in (4) 1 months
(5) sufferers themselves agrees to participate in this research, and signs Informed Consent Form person voluntarily.
Case exclusion standard
1) age < 20 one full year of life or > 60 one full year of life person.
2) above-mentioned diagnostic criteria person is not met.
3) I in above-mentioned luxuriant and rich with fragrance card staging scale is met, III, IV phase person.
4) serious cardiovascular system, digestive system, urinary system and disease of hematopoietic system person is associated with.
5) nervous system disease, psychotic disorder person is had.
6) allergic constitution person.
7) women of pregnancy women, women breast-feeding their children, preparation gestation.
8) person that do not sign Informed Consent Form.
Selector close standard of stating patient 100 example, wherein man 50 example, female 50 example, patient age 41-62 year, the mean age be (51.2 ± 3.6) year, be two groups by patient, be respectively treatment group 1 and treatment group 2, often group has 50 routine patients.Two groups of Genders, age, the course of disease, symptom there are no significant difference, have comparability (P > 0.05).
Treatment group 1 uses the capsule of preparation in embodiment 1 to treat, every day three times, oral 1 at every turn, continuously treatment 3 months.
Treatment group 2 uses the capsule of preparation in embodiment 2 to treat, every day three times, oral 1 at every turn, continuously treatment 3 months.
X-ray grade assessment scoring criteria
Respectively at treatment before, treatment 3 months after record 1 time.X-ray grade assessment scoring criteria table is as follows.
| Rank | Evaluation criteria | Score |
| 6 | Have no downright bad and cystis degeneration, femoral head without subsiding, acetabular bone and joint space normal | 100 |
| 5 | Necrotic area and cystis degeneration repair not yet completely, and femoral head has no and subsides, and hip joint is normal | 80 |
| 4 | There is downright bad cystis degeneration, collapse of the femoral head < 0.2cm, hip joint is normal | 60 |
| 3 | Collapse of the femoral head < 0.2cm, hip joint space is normal, and acetabular bone is without sclerosis | 40 |
| 2 | Collapse of the femoral head > 0.2cm, hip joint space slightly narrows, and acetabular bone slightly hardens | 20 |
| 1 | Femoral head obviously becomes flat, osteoarthritis sign serious as seen | 0 |
Curative effect determinate standard
X-ray checks curative effect determinate standard
1) take a turn for the better: x-ray inspection changes to upper level.
2) unchanged: x-ray checks unchanged.
3) be in progress: x-ray inspection changes to next stage.
Statistical method
Utilize SPSS13.0 software to process and analyze to experimental data, measurement data is with mean ± standard deviation
represent, adopt t inspection, enumeration data adopts x
2inspection, P < 0.05 represents that difference has statistical significance.
Therapeutic outcome
For treatment group 1, take a turn for the better 36 examples, unchanged 9 examples, progress 5 example, and effective percentage is 72%; For treatment group 2, take a turn for the better 42 examples, unchanged 5 examples, progress 3 example, and effective percentage is 84%; Two groups of total effective rate comparing differences have statistical significance (P < 0.05).The effect for the treatment of group 2 is better than the effect for the treatment of group 1.
Carry out the monitoring of blood, urine, stool routine examination and hepatic and renal function to two groups of patients before and after treatment, in time monitoring untoward reaction occurs, and it compares and sees the following form:
Claims (8)
1. treat the Chinese drugs agentia of bone stock head ischemic necrosis for one kind, it is characterized in that, it comprises the material of following weight portion: Radix Ginseng Rubra 15-25 part, Radix Astragali 20-50 part, Colla Corii Asini 10-20 part, Pheretima 10-15 part, Radix Angelicae Sinensis 10-25 part, Rhizoma Chuanxiong 10-25 part, Rhizoma Atractylodis Macrocephalae (parched) 10-15 part, stir-fried kidney beans 10-25 part, Radix Paeoniae Alba 10-20 part, Radix Curcumae 10-25 part, Cornu Cervi Pantotrichum 10-15 part, Os Cervi 20-30 part, Rhizoma Cibotii 10-30 part, Rhizoma Polygonati 20-30 part, Radix Notoginseng 50-100 part, Stigma Croci 10-15 part, Eupolyphaga Seu Steleophaga 10-25 part, Rhizoma Dioscoreae Nipponicae 10-25 part, Sanguis Draxonis 10-30 part, Radix Achyranthis Bidentatae 10-30 part, Radix Dipsaci 15-25 part, Ramulus Sambuci Williamsii 20-50 part, Radix Clematidis 15-25 part, Fructus Psoraleae 20-30 part, Rhizoma Gastrodiae 15-25 part, Rhizoma Et Radix Notopterygii 20-25 part, Radix Salviae Miltiorrhizae 20-25 part, Rhizoma Polygoni Cuspidati 15-25 part, Flos Echinopsis latifolii 15-20 part and Rhizoma Homalomenae 15-20 part.
2. the Chinese drugs agentia for the treatment of bone stock head ischemic necrosis according to claim 1, it is characterized in that, it comprises the material of following weight portion: Radix Ginseng Rubra 20 parts, the Radix Astragali 30 parts, 15 parts, Colla Corii Asini, Pheretima 12 parts, Radix Angelicae Sinensis 20 parts, Rhizoma Chuanxiong 20 parts, Rhizoma Atractylodis Macrocephalae (parched) 12 parts, stir-fried kidney beans 20 parts, the Radix Paeoniae Alba 15 parts, Radix Curcumae 20 parts, 12 parts, Cornu Cervi Pantotrichum, Os Cervi 25 parts, Rhizoma Cibotii 20 parts, Rhizoma Polygonati 25 parts, Radix Notoginseng 80 parts, Stigma Croci 12 parts, Eupolyphaga Seu Steleophaga 20 parts, Rhizoma Dioscoreae Nipponicae 20 parts, Sanguis Draxonis 20 parts, Radix Achyranthis Bidentatae 20 parts, Radix Dipsaci 20 parts, Ramulus Sambuci Williamsii 30 parts, Radix Clematidis 20 parts, Fructus Psoraleae 25 parts, 20 parts, Rhizoma Gastrodiae, Rhizoma Et Radix Notopterygii 22 parts, Radix Salviae Miltiorrhizae 22 parts, Rhizoma Polygoni Cuspidati 20 parts, Flos Echinopsis latifolii 18 parts and Rhizoma Homalomenae 18 parts.
3. the Chinese drugs agentia for the treatment of bone stock head ischemic necrosis according to claim 1 and 2, it is characterized in that, it also comprises the material of following weight portion: blue 10 parts of Iris speculatrix Hance 20 parts, Herba Stellariae Alsines 16 parts, Conyza canadensis (L.) Cronq. 15 parts, Lignum Xanthoceratis 12 parts, Rauvolfia verticillata 15 parts, Herba hyperici attenuati 18 parts, fingernail, Ramulus Et folium Spiraeae Acuminatae 9 parts, Radix seu Folium Cinnamomi angustifolii 11 parts and Radix grewiae bilobae 10 parts.
4. the Chinese drugs agentia for the treatment of bone stock head ischemic necrosis according to claim 3, it is characterized in that, described Chinese drugs agentia can be tablet, dispersible tablet, capsule, unguentum or decoction.
5. the purposes of compositions in the Chinese medicine of preparation treatment bone stock head ischemic necrosis, it is characterized in that described compositions comprises material Radix Ginseng Rubra 15-25 part of following weight portion, Radix Astragali 20-50 part, Colla Corii Asini 10-20 part, Pheretima 10-15 part, Radix Angelicae Sinensis 10-25 part, Rhizoma Chuanxiong 10-25 part, Rhizoma Atractylodis Macrocephalae (parched) 10-15 part, stir-fried kidney beans 10-25 part, Radix Paeoniae Alba 10-20 part, Radix Curcumae 10-25 part, Cornu Cervi Pantotrichum 10-15 part, Os Cervi 20-30 part, Rhizoma Cibotii 10-30 part, Rhizoma Polygonati 20-30 part, Radix Notoginseng 50-100 part, Stigma Croci 10-15 part, Eupolyphaga Seu Steleophaga 10-25 part, Rhizoma Dioscoreae Nipponicae 10-25 part, Sanguis Draxonis 10-30 part, Radix Achyranthis Bidentatae 10-30 part, Radix Dipsaci 15-25 part, Ramulus Sambuci Williamsii 20-50 part, Radix Clematidis 15-25 part, Fructus Psoraleae 20-30 part, Rhizoma Gastrodiae 15-25 part, Rhizoma Et Radix Notopterygii 20-25 part, Radix Salviae Miltiorrhizae 20-25 part, Rhizoma Polygoni Cuspidati 15-25 part, Flos Echinopsis latifolii 15-20 part and Rhizoma Homalomenae 15-20 part.
6. purposes according to claim 5, it is characterized in that, described compositions comprises the material of following weight portion: Radix Ginseng Rubra 20 parts, the Radix Astragali 30 parts, 15 parts, Colla Corii Asini, Pheretima 12 parts, Radix Angelicae Sinensis 20 parts, Rhizoma Chuanxiong 20 parts, Rhizoma Atractylodis Macrocephalae (parched) 12 parts, stir-fried kidney beans 20 parts, the Radix Paeoniae Alba 15 parts, Radix Curcumae 20 parts, 12 parts, Cornu Cervi Pantotrichum, Os Cervi 25 parts, Rhizoma Cibotii 20 parts, Rhizoma Polygonati 25 parts, Radix Notoginseng 80 parts, Stigma Croci 12 parts, Eupolyphaga Seu Steleophaga 20 parts, Rhizoma Dioscoreae Nipponicae 20 parts, Sanguis Draxonis 20 parts, Radix Achyranthis Bidentatae 20 parts, Radix Dipsaci 20 parts, Ramulus Sambuci Williamsii 30 parts, Radix Clematidis 20 parts, Fructus Psoraleae 25 parts, 20 parts, Rhizoma Gastrodiae, Rhizoma Et Radix Notopterygii 22 parts, Radix Salviae Miltiorrhizae 22 parts, Rhizoma Polygoni Cuspidati 20 parts, Flos Echinopsis latifolii 18 parts and Rhizoma Homalomenae 18 parts.
7. the purposes according to claim 5 or 6, it is characterized in that, described compositions also comprises the material of following weight portion: blue 10 parts of Iris speculatrix Hance 20 parts, Herba Stellariae Alsines 16 parts, Conyza canadensis (L.) Cronq. 15 parts, Lignum Xanthoceratis 12 parts, Rauvolfia verticillata 15 parts, Herba hyperici attenuati 18 parts, fingernail, Ramulus Et folium Spiraeae Acuminatae 9 parts, Radix seu Folium Cinnamomi angustifolii 11 parts and Radix grewiae bilobae 10 parts.
8. purposes according to claim 7, is characterized in that, described Chinese medicine can be tablet, dispersible tablet, capsule, unguentum or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510518675.XA CN105031540A (en) | 2015-08-24 | 2015-08-24 | Traditional Chinese medicine for treating ischemic femoral head necrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510518675.XA CN105031540A (en) | 2015-08-24 | 2015-08-24 | Traditional Chinese medicine for treating ischemic femoral head necrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105031540A true CN105031540A (en) | 2015-11-11 |
Family
ID=54438899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510518675.XA Pending CN105031540A (en) | 2015-08-24 | 2015-08-24 | Traditional Chinese medicine for treating ischemic femoral head necrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105031540A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074983A (en) * | 2016-08-19 | 2016-11-09 | 张建华 | A kind of treat the Chinese medicine preparation of femur head necrosis, capsule and preparation method thereof |
| CN106540141A (en) * | 2017-01-12 | 2017-03-29 | 张超英 | A kind of recovery pill for head of femur |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708324A (en) * | 2009-12-22 | 2010-05-19 | 薛艳修 | Plaster used for treating femoral head necrosis and preparation method thereof |
| CN101879262A (en) * | 2010-06-28 | 2010-11-10 | 刘振锋 | Chinese medicinal composition for treating femoral head necrosis |
| CN103142841B (en) * | 2013-03-29 | 2014-09-03 | 张好臣 | Traditional Chinese medicine composition for treating osteonecrosis of femoral head |
-
2015
- 2015-08-24 CN CN201510518675.XA patent/CN105031540A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708324A (en) * | 2009-12-22 | 2010-05-19 | 薛艳修 | Plaster used for treating femoral head necrosis and preparation method thereof |
| CN101879262A (en) * | 2010-06-28 | 2010-11-10 | 刘振锋 | Chinese medicinal composition for treating femoral head necrosis |
| CN103142841B (en) * | 2013-03-29 | 2014-09-03 | 张好臣 | Traditional Chinese medicine composition for treating osteonecrosis of femoral head |
Non-Patent Citations (1)
| Title |
|---|
| 董启文: ""健骨复肢胶囊治疗股骨头缺血性坏死的临床研究"", 《中国博士学位论文电子期刊WWW.CMFD.CNKI.NET》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074983A (en) * | 2016-08-19 | 2016-11-09 | 张建华 | A kind of treat the Chinese medicine preparation of femur head necrosis, capsule and preparation method thereof |
| CN106540141A (en) * | 2017-01-12 | 2017-03-29 | 张超英 | A kind of recovery pill for head of femur |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103028051B (en) | Kidney nourishing, blood circulation stimulating and pyralysis removing pill | |
| CN101428096B (en) | Chinese medicinal composition for treating femoral head necrosis and preparation method thereof | |
| CN105055804A (en) | Traditional Chinese medicine composition for treating lumbar disc herniation | |
| WO2022227331A1 (en) | Composition for preventing rheumatoid arthritis, preparation method therefor, and application thereof | |
| CN104383115A (en) | Traditional Chinese medicine preparation for treating coronary heart disease and preparation method of traditional Chinese medicine preparation | |
| CN101628054B (en) | Medicine for treating ischemic stroke and sequela thereof | |
| CN105031540A (en) | Traditional Chinese medicine for treating ischemic femoral head necrosis | |
| CN101607022B (en) | Chinese medicament bone-knitting pellet preparation | |
| CN101112537A (en) | Chinese traditional medicine preparations for treating hyperosteogeny disease | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN104107339A (en) | Traditional Chinese medicine for treating femoral head necrosis | |
| CN108853466A (en) | Tonifying kidney and strengthening yang Chinese medicine composition of integration of drinking and medicinal herbs and preparation method thereof | |
| CN102631542A (en) | Chinese medicament for treating coronary heart disease and preparation method thereof | |
| CN105169279A (en) | Traditional Chinese medicine composition for treating knee joint bone hyperplasia | |
| CN105287658A (en) | Application of medicine composition for preparing medicine for treating osteoporosis | |
| CN104840937A (en) | Traditional Chinese medicine preparation for treating osteoporosis | |
| CN104721802A (en) | TCM (traditional Chinese medicine) preparation for treating constrictive pericarditis and preparing method thereof | |
| CN103961655A (en) | Medicament for treating femoral head necrosis and preparation method thereof | |
| CN102370837A (en) | Kidney-invigorating and tendon-reinforcing capsule | |
| CN102961704A (en) | Pharmaceutical composition for treating liver caner and method for preparing dispersible tablets thereof | |
| CN102872287A (en) | Traditional Chinese medicine composition for treating femoral head necrosis and preparation method thereof | |
| CN105343862A (en) | Drug composition for soft tissue injury and fracture | |
| CN105412834A (en) | Application of traditional Chinese medicine composition in preparing medicine for treating CAD (Coronary Artery Disease) | |
| CN105456947A (en) | Pharmaceutical composition for treating avascular necrosis of femoral head and application thereof | |
| CN105194088A (en) | Traditional Chinese medicine preparation for treating cerebral apoplexy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151111 |
|
| RJ01 | Rejection of invention patent application after publication |